{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.9","upperLimit":"2.1","value":"2.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"}],"units":"Participants"}],"description":"PFS was defined as the time from first day of study treatment to the first documented PD or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of ≥1 new lesions was also considered PD. PFS as assessed by blinded independent central review per RECIST 1.1 was reported per protocol for the first course of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants receive pembrolizumab 200 mg IV Q3W for up to 35 treatments (approximately 2 years).","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 67 months","title":"Progression Free Survival (PFS) According to RECIST 1.1 Assessed by BICR","type":"SECONDARY","unitOfMeasure":"Months"}